- Exchange: Tokyo
- Sector: Health Care
- Industry: Health Care Facilities/Srvcs
- Sub-Industry: Health Care Services
Shin Nippon Biomedical Laboratories Ltd
+ Add to Watchlist2395:JP
1,400 JPY 50 3.45%As of 01:37:12 ET on 06/19/2013.
Snapshot for Shin Nippon Biomedical Laboratories Ltd (2395)
| Open: | 1,480 | Day's Range: | 1,386 - 1,493 | Volume: | 638,300 |
|---|---|---|---|---|---|
| Previous Close: | 1,450 | 52wk Range: | 186 - 2,540 | 1-Yr Rtn: | +566.67% |
Key Statistics for 2395
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(03/2014) | - |
| Relative P/E vs. TPX | - |
| Earnings Per Share (JPY) (ttm) | -33.5600 |
| Est. EPS (JPY) (03/2014) | -27.7000 |
| Est. PEG Ratio | - |
| Market Cap (M JPY) | 48,081.60 |
| Shares Outstanding (M) | 34.34 |
| 30 Day Average Volume | 1,351,197 |
| Price/Book (mrq) | 17.7103 |
| Price/Sale (ttm) | 2.8030 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (JPY) | - |
| Last Dividend | 03/27/2014 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/13/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for 2395
Company Profile & Key Executives for 2395
Shin Nippon Biomedical Laboratories Ltd is a contract research organization. The Company provides pre-clinical testing services in the pharmaceutical industry.
| Ryoichi NagataPresident/CEO | Toshihiko SekiExecutive Vice President |
| Koichiro FukuzakiSenior Managing Director | Ken TakanashiSenior Managing Director |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
2395 News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page